Unmasking the lung cancer epigenome

Annual Review of Physiology

Volumn 77, Issue , 2015, Pages 453-474

  Belinsky, Steven A ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Aerosol delivery; Chromatin remodeling; Demethylation therapy; Epigenetics; MicroRNA; Promoter methylation

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; DNA; MICRORNA; RAS PROTEIN;

APOPTOSIS; ARTICLE; BRONCHIAL EPITHELIAL CELL; CANCER GENETICS; CANCER THERAPY; CELL ADHESION; CELL INVASION; DNA REPAIR; EPIGENETICS; EPITHELIUM CELL; GENE SILENCING; HUMAN; LUNG CANCER; METHYLATION; NONHUMAN; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ANIMAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE MODEL; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; IN VITRO STUDY; LUNG TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE MODELS, ANIMAL; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IN VITRO TECHNIQUES; LUNG NEOPLASMS; MICRORNAS; PHENOTYPE; PRECANCEROUS CONDITIONS; PROMOTER REGIONS, GENETIC; RATS;

EID: 84922765422     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021014-072018     Document Type: Article

References (141)

1. Siegel R, Ma J, Zou Z, Jemal A. 2014. Cancer statistics. CA Cancer J. Clin. 64:9-29
2. Hecht SS. 2008. Progress and challenges in selected areas of tobacco carcinogenesis. Chem. Res. Toxicol. 21:160-71
3. Slaughter DP, Southwick HW, Smejkal W. 1953. "Field cancerization" in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 5:963-68
4. Auerbach O, Hammond EC, Garfinkel L. 1979. Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 versus 1970-1977. N. Engl. J. Med. 300:381-85
5. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, et al. 2002. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 62:2370-77
6. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM. 1997. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst. 89:834-36
7. Bunn PA Jr, Franklin W, Doebele RC. 2013. The evolution of tumor classification: a role for genomics? Cancer Cell 24:693-94
8. Riessk J. 2013. Shifting paradigms in non-small cell lung cancer: an evolving therapeutic landscape. Am. J. Manag. Care 19:390-97
9. Timp W, Feinberg AP. 2013. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer 13:497-10
10. Hanahan D,Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-74
11. Gardiner-Garden M, Frommer M. 1987. CpG islands in vertebrate genomes. J. Mol. Biol. 196:261-82
12. Bestor TH. 2000. The DNA methyltransferases of mammals. Hum. Mol. Genet. 9:2395-402
13. McCade MT, Brandes JC, Vertino PM. 2009. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin. Cancer Res. 15:3927-37
14. Ting AH,McGarvey KM, Baylin SB. 2006. The cancer epigenome-components and functional correlates. Genes Dev. 20:3215-31
15. Jones PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128:683-92
16. Albert M, Helin K. 2010. Histone methyltransferases in cancer. Semin. Cell Dev. Biol. 21:209-20
17. Breuer RHJ, Snijders PJF, Smit EF, Sutedja TG, Sewalt RGAB, et al. 2004. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6:736-43
18. Watanabe H, Soejima K, Yasuda HY, Kawada I, Nakachi I, et al. 2008. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int. 8:15
19. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, et al. 2010. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 70:7830-40
20. Schlesinger Y, Straussman R,Keshet I, Farkash S, HechtM, et al. 2007. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39:232-36
21. Gal-Yam EM, EggerG, Iniguez L,Holster H, Einarsson S, et al. 2008. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc. Natl. Acad. Sci. USA 105:12979-84
22. Jin B, Yao B, Li J-L, Fields CR, Delmas AL, et al. 2009. DNMT1 and DNMT3B modulate distinct polycomb-mediated histone modifications in colon cancer. Cancer Res. 69:7412-21
23. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. 2006. The polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871-74
24. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. 2006. Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125:301-13
25. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, et al. 2007. Epigenetic stem cell signature in cancer. Nat. Genet. 39:157-58
26. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. 2007. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 39:237-42
27. TachibanaM,Matsumura Y, Fukuda M, Kimura H, Shinkai Y. 2008. G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. EMBO J. 27:2681-90
28. Serrano M, Hannon GJ, Beach D. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 16:704-7
29. Kamb A, GruisNA, Weaver-Feldhaus J,Liu Q, Harshman K, et al. 1994.Acell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-40
30. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al. 1995. 5-CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:633-34
31. Zöchbauer-Muller S, FongKM, Virmani AK,Geradts J, Gazdar AF,Minna JD. 2001. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61:249-55
32. Kim D-H, Nelson HH, Wiencke JK, Zheng S, Christiani DC, et al. 2001. p16INK4a and histologyspecific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 61:3419-24
33. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, et al. 1998. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA 95:11891-96
34. Lukas J, Parry D, Aaqaard L, Mann DJ, Bartkova J, et al. 1995. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375:503-6
35. Weinberg RA. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-30
36. Harbour JW, Lai SL,Whang-Peng J, Gazdar AF,Minna JD, Kaye FJ. 1988. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353-57
37. Foster SA,Wong DJ, Barrett MT,Galloway DA. 1998. Inactivation of p16 in humanmammary epithelial cells by CpG island methylation. Mol. Cell. Biol. 18:1793-801
38. Wong DJ, Foster SA, Galloway DA, Reid BJ. 1999. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M0 growth arrest. Mol. Cell. Biol. 19:5642-51
39. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93:9821-26
40. Licchesi JD, Westra WH, Hooker CM, Heman JG. 2008. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin. Cancer Res. 14:2570-78
41. Pulling LC, Divine KK, Klinge DM, Gilliland FD, Kang T, et al. 2003. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res. 64:4742-48
42. EstellerM,Hamilton SR, Burger PC, Baylin SB,Herman JG. 1999. Inactivation of theDNArepair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:793-97
43. Furonaka O, Takeshima Y, Aways H, Kushitani K, Kohno N, Inai K. 2005. Aberrant methylation and loss of expression of O6-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma. Pathol. Int. 55:303-9
44. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. 2000. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 60:2368-71
45. Yin D, Xie D, Hofmann WK, Zhang W, Asotra K, et al. 2003. DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol. Carcinog. 36:23-31
46. Gomes A, Reis-SilvaM, Alarcao A, Couceiro P, Sousa V, Carvalho L. 2014. Promoter hypermethylation of DNA repair genesMLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung. Rev. Port. Pneumol. 20:20-30
47. Cohen O, Feinstein E, Kimchi A. 1997. DAP-kinase is a Ca2+/calmodulin-dependent, cytoskeletalassociated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J. 16:998-108
48. Cohen O, Inbal B, Kissil JL, Raveh T, Berissi H, et al. 1999. DAP-kinase participates in TNF-α and Fas-induced apoptosis and its function requires the death domain. J. Cell Biol. 146:141-48
49. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, et al. 2000. Hypermethylation of the death-Associated protein (DAP) kinase promoter and aggressiveness in stage I non-small cell lung cancer. J. Natl. Cancer Inst. 92:1511-16
50. Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, et al. 2001. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 20:1765-70
51. Toyooka A, Toyooka KO, Miyajima K, Reddy JL, Toyota M, et al. 2003. Epigenetic down-regulation of death-Associated protein kinase in lung cancers. Clin. Cancer Res. 9:3034-41
52. Raveh T, Drouguett G, Horwitz MS, DePinho RA, Kimchi A, et al. 2001. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat. Cell Biol. 3:1-7
53. Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, et al. 2002. Differential inactivation of caspase-8 in lung cancers. Cancer Biol. Ther. 1:65-69
54. Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, et al. 2003. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors byDNAmethylation. Cell Death Differ. 10:356-64
55. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. 1998. Increasing complexity of Ras signaling. Oncogene 17:1395-413
56. Downward J. 2001. The ins and outs of signaling. Nature 411:759-62
57. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. 2000. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 25:315-19
58. Burbee DG, Forqacs E, Zöchbauer-Muller S, Shivakumar L, Fong K, et al. 2001. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst. 93:691-99
59. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, et al. 2002. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 12:253-65
60. Hesson L, Dallol A, Minna JD, Maher ER, Latif F. 2003. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22:947-54
61. Thaler S, Hahnel PS, Schad A, Dammann R, Schuler M. 2009. RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res. 59:1748-57
62. Takeichi M. 1991. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251:1451-55
63. Chambers AF,MatrisianLM.1997. Changing views of the role of matrix metalloproteinases inmetastasis. J. Natl. Cancer Inst. 89:1260-70
64. Colognato H, Yurchenco PD. 2000. Form and function: the laminin family of heterotrimers. Dev. Dyn. 218:213-34
65. Giannelli G, Antonaci S. 2000. Biological and clinical relevance of laminin-5 in cancer. Clin. Exp.Metastasis 18:439-43
66. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, et al. 2001. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 6:4556-60
67. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:404-15
68. Polyak K, Weinberg RA. 2009. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9:265-73
69. Bachman KE, Herman JG, Corn PG,Merlo A, Costello JF, et al. 1999. Methylation-Associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res. 59:798-802
70. Sathyanarayana UB, Toyooka S, Padar A, Takahashi T, Brambilla E, et al. 2003. Epigenetic inactivation of laminin-5-encoding genes in lung cancers. Clin. Cancer Res. 9:2665-72
71. Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, et al. 2005. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin. Cancer Res. 11:2954-61
72. Heller G, Fong KM, Girard L, Seidi S, End-Pfutzenreuter A, et al. 2006. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 25:959-68
73. Korinek V, Barker N, Morin PJ, Van Wichen D, de Weger R, et al. 1997. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/-colon carcinoma. Science 275:1784-87
74. Morin PJ, Sparks AB, Lorinek V, Barker N, CleversH, et al. 1997. Activation ofβ-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275:1787-90
75. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW, et al. 1998. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58:1130-34
76. Licchesi JD, Westra WH, Hooker CM, Achida EO, Baylin SB,Herman JG. 2008. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 29:895-904
77. Fukui T, Kondo M, Ito G, Maeda O, Sata N, et al. 2005. Transcriptional silencing of secreted frizzled related protein 1 (SFRP1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 24:6323-27
78. Mazieres J, He B, You L, Xu Z, Lee AY, et al. 2004. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 64:4717-20
79. Guo M, Akiyama Y, House MG, Hooker CM, Heath E, et al. 2004. Hypermethylation of the GATA genes in lung cancer. Clin. Cancer Res. 10:7917-24
80. Akiyama Y, Watkins N, Suzuki H, Jair KW, van Engeland M, et al. 2003. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol. Cell. Biol. 23:8429-39
81. Busslinger M,Klix N, Pfeffer P, Graninger PG, Kozmik Z. 1996. Deregulation of PAX-5 by translocation of the Eμenhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc. Natl. Acad. Sci. USA 93:6129-34
82. PalmisanoWA, Crume KP, Grimes MJ,Winters SA, Toyota M, et al. 2003. Aberrant promoter methylation of the transcription factor genes PAX5 αand βin human cancers. Cancer Res. 63:4620-25
83. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. 1992. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol. Cell. Biol. 12:2662-72
84. Tessema M, Yu YY, Stidely CA, Machida EO, Schuebel KE, Baylin SB. 2009. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 30:1132-38
85. Hsu HK, Weng YI, Hsu PY, Huang TH, Huang YW. 2014. Detection of DNA methylation byMeDIP and MBDCap assays: an overview of techniques. Methods Mol. Biol. 1105:61-70
86. Estécio MR, Yan PS, Ibrahim AE,TellezCS, Shen L, et al. 2007. High-THroughput methylation profiling by MCA coupled to CpG island microarray. Genome Res. 17:1529-36
87. Kalari S, Jung M, Kernstine KH, Takahashi T, Pfeifer GP. 2013. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene 32:3559-68
88. Schuebel KE, ChenW, Cope L, Gl ockner SC, Suzuki H, et al. 2007. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 3:1709-23
89. Tessema M, Yingling CM, Liu Y, Tellez CS, Van Neste L, et al. 2014. Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. Carcinogenesis 35:1248-57
90. Tessema M, Klinge DM, Yingling CM, Do K, Van Neste L, Belinsky SA. 2010. Re-expression of the CXCL14 chemokine, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene 29:5159-70
91. Naeem H, Wong NC, Chatterton Z, Hong MK, Pedersen JS, et al. 2014. Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. BMC Genomics 15:51
92. Sato T, Aral E, Kohno T, Tsuta K,Watanabe S, et al. 2013. DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma. PLoS ONE 8:e59444
93. Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, et al. 2013. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J. Clin. Oncol. 31:4140-47
94. Darash-YahanaM, Gillespie JW, Hewitt SM, Chen YY, Maeda S, et al. 2009. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-Associated cancers. PLoS ONE 4:e6695
95. Hromas R, Broxmeyer HE, Kim C, Nakshatri H, Christopherson K 2nd, et al. 1999. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem. Biophys. Res. Commun. 255:703-6
96. Mu X, Chen Y, Wang S, Huang X, Pan H, Li M. 2009. Overexpression of VCC-1 gene in human hepatocellular carcinoma cells promotes cell proliferation and invasion. Acta Biochim. Biophys. Sin. 41:631-37
97. Strieter RM, Belperio JA, Burdick MD, Sharma S, Dubinett SM, Keane MP. 2004. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann. N. Y. Acad. Sci. 1028:351-60
98. Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, et al. 2004. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res. 64:8262-70
99. Shurin GV, Ferris RL, Tourkova IL, Perez L, Lokshin A, et al. 2005. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J. Immunol. 174:5490-98
100. Teneng I, Tellez CS, Picchi MA, Klinge DM, Yingling CM, et al. 2014Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer. Oncogene. In press
101. Ozsolak F, Poling LL, Wang Z, LiuH, Liu XS, et al. 2008. Chromatin structure analyses identifymiRNA promoters. Genes Dev. 22:3172-83
102. He L, Hannon GJ. 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5:522-31
103. Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B, et al. 2012. Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets forDNAmethylation in non-small cell lung cancers. Clin. Cancer Res. 18:1619-29
104. Watanabe K, Emoto N, Hamano E, Sunohara M, Kawakami M, et al. 2012. Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int. J. Cancer 130:2580-90
105. Corney DC, Fleskin-Niktin A, Godwin AK,WangW, Niktin AY. 2007. MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 67:8433-38
106. Nadal E,ChenG,Gallegos M, Lin L, Ferrer-TorresD. 2013. Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin. Cancer Res. 19:6842-52
107. Xi S, Xu H, Shan J, Tao Y, Hong JA. 2013. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J. Clin. Investig. 123:1241-61
108. Rykov SV, Khodyrev DS, Pronina IV, Kazubskaya TP, Loginov VI, Braga EA. 2013. Novel miRNA genes methylated in lung tumors. Genetika 49:896-901
109. Tan W, Gu J, Huang M, Wu X, Hildebrandt MA. 2014. Epigenetic analysis of microRNA genes in tumors from surgically resected lung cancer patients and association with survival. Mol. Carcinog. In press
110. Lujambio A, EstellerM. 2007. CpG island hypermethylation of tumor suppressormicroRNAs in human cancer. Cell Cycle 6:1455-59
111. Zhu X, Li Y, Shen H, Li H, Long L, Hui L. 2013. miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Lett. 587:73-81
112. Cao J, Song Y, Bi N, Shen J, Liu W, et al. 2013. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 73:3326-35
113. Li N, Zhang F, Li S, Zhou S. 2014. Epigenetic silencing of microRNA-503 regulates FANCA expression in non-small cell lung cancer cell. Biochem. Biophys. Res. Commun. 444:611-16
114. Damiani LA, Yingling CM, Leng S, Romo PE, Nakamura J, Belinsky SA. 2008 Carcinogen-induced gene promoter hypermethylation ismediated byDNMT1and causal for transformation of immortalized bronchial epithelial cells. Cancer Res. 68:9005-14
115. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, et al. 2004. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64:9027-34
116. Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, et al. 2011. Carcinogen exposure induces EMT through epigenetic silencing of miR-205 and miR-200 family and promotes stem-like phenotype during transformation of lung epithelial cells. Cancer Res. 71:3087-97
117. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. 2007. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 39:237-42
118. Azim HA Jr, Ganti AK. 2006. Targeted therapy in advanced non-small cell lung cancer (NSCLC): Where do we stand? Cancer Treat. Rev. 32:630-36
119. Dy GK, Adjei AA. 2006. Angiogenesis inhibitors in lung cancer: a promise fulfilled. Clin. Lung Cancer 7(Suppl. 4):145-49
120. SandlerA,HerbstR. 2006. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin. Cancer Res. 12:S4421-25
121. Spicer J, Chowdhury S, Harper P. 2007. Targeting novel and established therapies for non-small cell lung cancer. Cancer Lett. 250:9-16
122. Auberger J, Loeffler-Ragg J, Wurzer W, Hilbe W. 2006. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Curr. Cancer Drug Targets 6:271-94
123. Bunn PA Jr, Dziadziuszko R, Varella-Garcia M, Franklin WA,Witta SE, et al. 2006. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin. Cancer Res. 12:3652-56
124. Herman JG, Baylin SB. 2003. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349:2042-54
125. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:103-7
126. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, et al. 2006. DNA methylation changes after 5-Aza-2-deoxycytidine therapy in patients with leukemia. Cancer Res. 66:5495-503
127. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, et al. 2006. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66:6361-69
128. Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG. 2003. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 63:7089-93
129. March TH, Marron-Terada PG, Belinsky SA. 2001. Refinement of an orthotopic lung cancer model in the nude rat. Vet. Pathol. 38:483-90
130. Belinsky SA, Grimes MJ, Picchi MA, Mitchell HD, Stidley CA, et al. 2011. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res. 71:454-62
131. Juergens RA,Wrangle J, Vendetti FP,Murphy SC, Zhao M, et al. 2011. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1:598-607
132. Ho DH, Frei E. 1971. Clinical pharmacology of 1-β-darabinofuranosyl cytosine. Clin. Pharmacol. Ther. 12:944-54
133. Fitzgerald SM, Royal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE. 2006. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum. Genet. 119:276-83
134. Mahfouz RZ, Jankowska A, Ebrahem Q,GuX, VisconteV, et al. 2013. IncreasedCDAexpression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-Azacytidine or decitabine therapy. Clin. Cancer Res. 19:938-48
135. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T. 2011. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. J. Clin. Oncol. 29:2521-27
136. Reed MD, Tellez CS, Grimes MJ, Picchi MA, Tessema M, et al. 2013. Aerosolized 5-Azacytidine suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Br. J. Cancer 109:1775-81
137. Liu F, Barsyte-Lovejoy D, Allali-Hassani A, He Y, Herold JM, et al. 2011. Optimization of cellular activity of G9a inhibitors 7-Aminoalkoxy-quinazolines. J. Med. Chem. 54:6139-50
138. Dhanak D. 2012. Inhibition of methyltransferase EZH2. Cancer Res. 72:SY02 (Abstr.)
139. Champiat S, Ileana E, Giaccone G, Besse B, MountziosG, et al. 2014. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J. Thorac. Oncol. 9:144-53
140. Wrangle J,WangW, Koch A, Easwaran H, Mohammad HP. 2013. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4:2067-79
141. Velcheti V, Schalper KA, CarvajalDE, Anagnostou VK, Syrigos KN. 2013. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig. 94:107-16